Sulfamates as antiglaucoma agents

A pharmaceutical composition for lowering intraocular pressure in a mammal comprising an effective amount of a compound of the formula:

• (HO).sub.p --A--[--OS(O).sub.2 NR.sup.1 R.sup.2 ].sub.z
• wherein
• A is aryloxy-alkyl, in which the aryl moiety is a substituted phenyl group of the formula:
• ##STR11## where X is hydrogen, halo, CF.sub.3, nitro-, --SO.sub.2 NR.sub.1 R.sub.2, loweralkoxy, hydroxy, amino, loweralkylamino, diloweralkylamino, methylcarbonylamino, loweralkyl, methyloxycarbonyl, 1H-imidazol-1-yl, 3-thiazole, 1-pyrrole, phenyl, 1H-triazol-1-yl, cyano, 2-loweralkyl-1H-imidazol-1-yl, 4-loweralkyl-1H-imidazol-1-yl, 4-phenyl-1H-imidazol-1-yl, --COOH, --COOM wherein M is a pharmaceutically acceptable metal cation, aryloxy or aroyl;
• Y is hydrogen, halo, loweralkoxy, hydroxy or loweralkyl;
• and
• W is hydrogen, loweralkoxy or loweralkyl;
• and said alkyl portion of A being substituted on one or more carbon atoms by the
• depicted sulfamyloxy group, where Z is the number of --OS(O).sub.2 NR.sup.1 R.sup.2 groups present on the alkyl moiety of A and is always at least one;
• p is the number of hydroxyl groups present of the alkyl moiety of A which have not been converted to --OS(O).sub.2 NR.sup.1 R.sup.2 groups, including zero;
• R.sup.1 is hydrogen or loweralkyl;
• R.sup.2 is hydrogen, loweralkyl, --CO.sub.2 R.sup.1, or --CO.sub.2 M+wherein M is defined above;
• and the pharmaceutically acceptable salts thereof when they can be formed and the optical isomers thereof, when they can be formed, and a pharmaceutically acceptable carrier.

A pharmaceutical composition for topical administration to the eye of a mammal in need thereof comprising an effective amount of a water soluble compound having the formula:

• (HO).sub.p --[OSO.sub.2 NH.sub.2 ].sub.2
• wherein:
• A is aryloxy-alkyl in which the aryl moiety is a substituted phenyl group of the formula:
• ##STR12## wherein X is amino, loweralkylamino, diloweralkylamino, 1H-imidazol-1-yl, 4-loweralkyl-1H-imidazol-1-yl, 1H-triazol-1-yl, --COOH or --COOM wherein M is a pharmaceutically acceptable cation;
• Y is hydrogen, halo, loweralkoxy, hydroxy or loweralkyl;
• W is hydrogen, loweralkoxy or loweralkyl;
• and said alkyl portion of A being substituted on one or more carbon atoms by the depicted sulfamoyloxy group, where Z is the number of --OS(O).sub.2 NH.sub.2 groups present and is always at least one;
• p is the number of hydroxygroups present on the alkyl moiety of A which have not been converted to --OS(O).sub.2 NH.sub.2 groups, including zero;
• or a pharmaceutically acceptable salt thereof when they can be formed;
• the optical isomers thereof when they can be formed;
• and a pharmaceutically acceptable carrier.